A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
|Articles|December 1, 1998
The American Journal of Managed Care
- December 1998
- Volume 4
- Issue 12
Pharmacist Compensation for Ambulatory Patient Care Services
Advertisement
Articles in this issue
almost 28 years ago
Evaluation of Anemiaalmost 28 years ago
The Role of Clinical Practice Guidelines in Disease Managementalmost 28 years ago
Trends in Costs of Percutaneous Transluminal Coronary AngioplastyAdvertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Drug Price Drives Value of MASH Therapies More Than Efficacy
5